Even small volume can send the SP tumbling so easily.The new appointments seem strong and hopefully some real development work isn't too far away.Although, I wonder what those investors that paid up at 45c/share are now thinking...
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%